BR100 Increased By (1.02%)
BR30 Increased By (1.71%)
KSE100 Increased By (0.58%)
KSE30 Increased By (0.65%)
BECO 6.03 Increased By ▲ 0.26 (4.51%)
BML 52.61 Decreased By ▼ -0.39 (-0.74%)
BOP 34.23 Increased By ▲ 0.24 (0.71%)
CNERGY 8.16 Increased By ▲ 0.05 (0.62%)
DCL 12.23 Increased By ▲ 0.03 (0.25%)
FCCL 53.80 Increased By ▲ 0.97 (1.84%)
FCSC 5.24 Increased By ▲ 0.17 (3.35%)
FFL 18.03 Increased By ▲ 0.08 (0.45%)
FNEL 1.30 Increased By ▲ 0.01 (0.78%)
HUMNL 11.00 Increased By ▲ 0.12 (1.1%)
KEL 8.07 Increased By ▲ 0.05 (0.62%)
KOSM 5.39 Decreased By ▼ -0.13 (-2.36%)
MLCF 87.90 Increased By ▲ 1.39 (1.61%)
NBP 186.60 Increased By ▲ 1.44 (0.78%)
PACE 10.75 Increased By ▲ 0.17 (1.61%)
PAEL 39.95 Increased By ▲ 0.53 (1.34%)
PIAHCLA 26.19 Decreased By ▼ -0.03 (-0.11%)
PIBTL 17.32 Increased By ▲ 0.65 (3.9%)
PPL 233.49 Increased By ▲ 5.31 (2.33%)
PRL 34.98 Increased By ▲ 0.30 (0.87%)
PTC 67.71 Increased By ▲ 2.38 (3.64%)
SEARL 90.90 Increased By ▲ 0.77 (0.85%)
SSGC 27.20 Increased By ▲ 0.60 (2.26%)
TELE 8.57 Increased By ▲ 0.29 (3.5%)
THCCL 60.85 Increased By ▲ 2.35 (4.02%)
TPLP 8.78 Increased By ▲ 0.56 (6.81%)
TREET 24.65 Increased By ▲ 0.12 (0.49%)
TRG 71.50 Increased By ▲ 1.79 (2.57%)
WAVES 10.01 Increased By ▲ 0.07 (0.7%)
WTL 1.27 Decreased By ▼ -0.01 (-0.78%)
Topic

Oxford vaccine

Britain recommends not using Oxford/AstraZeneca vaccine for under-30s

Britain recommends not using Oxford/AstraZeneca vaccine for under-30s

Published 07 Apr, 2021 08:09pm
  • "We are not advising a stop to any vaccination for any individual in any age group. We are advising a preference for one vaccine over another vaccine for a particular age group, really out of the utmost caution, rather than because we have any serious safety concerns," he said at a briefing. It came after Britain's MHRA medicine regulator identified a possible side-effect from the COVID-19 vaccine developed by Oxford University and AstraZeneca involving rare brain blood clotting.
AstraZeneca/Oxford vaccine more effective with longer dose gap: study

AstraZeneca/Oxford vaccine more effective with longer dose gap: study

Published 19 Feb, 2021 09:17pm
  • The study confirmed the Anglo-Swedish drugmaker's findings from earlier this month that showed the vaccine had 76% efficacy against symptomatic coronavirus infection for three months after the first dose.
  • Efficacy was found to be at 81% with the longer interval of 12 weeks between the first and second dose, compared with 55% efficacy up to the six-week gap.
South Africa offers AstraZeneca jabs to AU

South Africa offers AstraZeneca jabs to AU

Published 17 Feb, 2021 11:06am
  • "The first batch of Johnson & Johnson Covid-19 vaccines have arrived at OR Tambo International Airport," Mkhize tweeted as the precious cargo landed in the financial capital Johannesburg.
Different age rules for Oxford/AstraZeneca COVID-19 vaccine in EU

Different age rules for Oxford/AstraZeneca COVID-19 vaccine in EU

Published 08 Feb, 2021 08:32pm
  • Some EU countries, though, have limited its use to people under 65 because of a lack of data for older people in clinical trials for the shot.
  • Countries that have recommended the vaccine's use for people between 18 and 64 years old:
Oxford says COVID-19 vaccine with AstraZeneca works against UK variant

Oxford says COVID-19 vaccine with AstraZeneca works against UK variant

Published 05 Feb, 2021 07:38pm
  • Britain had said that it believed the vaccines were effective against variants that are circulating in the UK.
  • Data from our trials of the ChAdOx1 vaccine in the United Kingdom indicate that the vaccine not only protects against the original pandemic virus.
Loading...